| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,889.8 | 1,412.3 |
| Gross profit | 1,672.9 | 1,215.8 |
| Profit before tax | 410.4 | 147.2 |
| Net income | 384.7 | 124.8 |
| EPS (diluted, $ a share) | $0.25 | $0.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +208.2% |
|---|---|
| Revenue, year on year | +33.8% |
| Gross margin | 88.5% |
| Operating margin | 22.2% |
10-Q filed with the SEC, NASDAQ: ONC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BeOne Medicines Ltd.: key numbers
- Share price
- $411.29Close, Nov 16
- Shares outstanding
- 1.48BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BeOne Medicines Ltd.
All →BeOne Medicines Principal Accounting Officer Titus B. Ball Sells $632K of Stock
Titus B. Ball, Principal Accounting Officer, sold 1,559 shares of BeOne Medicines Ltd. at $405.55 to $406.34 a share (average $405.57) in 2 transactions, worth $632K in total on Nov 6, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $632K
- Shares
- 1,559
- Average price
- $405.57
- Role
- Principal Accounting Officer
- Holding change
- -100.0%
- Trade date
- Nov 6, 2026
BeOne Medicines SVP, General Counsel Chan Henry Lee Sells $447K of Stock
Chan Henry Lee, SVP, General Counsel, sold 1,115 shares of BeOne Medicines Ltd. at $400.00 to $402.00 a share (average $400.82) in 2 transactions, worth $447K in total on Nov 5, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $447K
- Shares
- 1,115
- Average price
- $400.82
- Role
- SVP, General Counsel
- Holding change
- -100.0%
- Trade date
- Nov 5, 2026
BeOne Medicines Financial Results
BeOne Medicines reported third quarter 2026 total global revenues of $1.9 billion, a 34% increase year-over-year, driven by strong sales of its BTK inhibitor BRUKINSA. The company achieved GAAP net income of $384.7 million and raised its full-year 2026 revenue guidance to a range of $6.9 billion to $7.0 billion.
- Term
- 3 months
“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI.”
John V. Oyler, Co-Founder, Chairman, and CEO
BeOne Medicines Insider Xiaodong Wang Sells $11.3M of Stock
Xiaodong Wang sold 31,028 shares of BeOne Medicines Ltd. at $355.56 to $366.22 a share (average $362.97) in 11 transactions, worth $11.3M in total on Oct 27, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $11.3M
- Shares
- 31,028
- Average price
- $362.97
- Holding change
- -100.0%
- Trade date
- Oct 27, 2026
BeOne Medicines Insider Xiaodong Wang Sells $10.9M of Stock
Xiaodong Wang sold 31,027 shares of BeOne Medicines Ltd. at $349.56 to $353.24 a share (average $350.99) in 5 transactions, worth $10.9M in total on Oct 13, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $10.9M
- Shares
- 31,027
- Average price
- $350.99
- Holding change
- -100.0%
- Trade date
- Oct 13, 2026
BeOne Medicines SVP, General Counsel Chan Henry Lee Sells $418K of Stock
Chan Henry Lee, SVP, General Counsel, sold 1,115 shares of BeOne Medicines Ltd. at $375.00 a share, worth $418K in total on Sep 30, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $418K
- Shares
- 1,115
- Price
- $375.00
- Role
- SVP, General Counsel
- Holding change
- -100.0%
- Trade date
- Sep 30, 2026